Chantal Le Chat Appointed to Robocath As An Independent Member of the Strategic Committee: Boasts 35 + Years of Skill

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

December 14, 2020

Chantal Le Chat boasts 35 years of skill and know-how built up while working in a range of posts at the major player in imaging, GE Healthcare.

Over the last six years, Chantal Le Chat has occupied key strategic roles in the company’s Interventional Division, including Global GM. Her duties as an independent member of the Strategic Committee will include supporting the governance of Robocath.*

She will use her extensive knowledge of imaging systems to analyze strategic opportunities for promoting interoperability of equipment used in cath labs, in particular, compatibility with R-One™, the first robotic platform, as well as future robotic generations.

Philippe Bencteux, President and founder of Robocath, said: “I’m honored that a leader in medical interventional imaging such as Chantal shares our vision for robot-controlled vascular operations. I’m excited to welcome her to the Strategic Committee. Her impressive experience will be key in advancing future developments at Robocath.”

Lucien Goffart, CEO of Robocath, added: “I’m also delighted that we’ve been able to boost our Strategic Committee by appointing Chantal. The sector is currently seeing significant changes, with the advent of new technologies that promise substantial added value. Robotics makes up a key part of this trend. New robotics projects will need to predict and embrace changes in the sector in order to ensure that they remain relevant in the market over the medium and long term. Chantal’s experience working for a leading imaging company will help us to quickly identify which technological development opportunities to focus on in order to speed up implementation and lock in growth.”

Chantal Le Chat, Independent Strategic Committee Member at Robocath, said: “I’m happy to be joining the Strategic Committee at Robocath. I’ve been following the company and its progress for a number of years and I’m especially impressed with the strides it has taken since being awarded CE marking in February 2019 for its first robot”

“The company is now right at the heart of a revolution in interventional medicine, which comes with a number of benefits for physicians, such as greater comfort and complete protection from X-rays, while the level of precision a robot can deliver is a boon for patients. Robocath’s commercial expansion is highly promising and, with its integration in the cath lab, the product should see significant growth. I’m looking forward to using my experience to help the company achieve its goals,” concluded Chantal Le Chat.

Chantal Le Chat joined GE Healthcare in 1985 as an engineer. She then held various leadership roles in Engineering within the XRay tube division as well as the Vascular organization based in Buc (France) and Milwaukee (Wisconsin, US). In 2000, she moved to the Service organization, leading Service Operations for EMEA before becoming, in 2002, the Service GM for France-Belgium-Luxemburg. In this role, she drove customer satisfaction, operational excellence, and profitable growth.

In 2005, Chantal Le Chat was promoted to EMEA Product GM for Surgery, Interventional & XRays and successfully developed the business for five years. In 2010, she became the Global Segment GM for Premium Angiography and Hybrid-OR. In this role, she drove market creation and introduced disruptive products and applications such as the Discovery IGS 7 platform. In mid-2014, she expanded her role to also cover the CardioVascular segment and became the Global GM for Interventional. Chantal holds an Engineering degree in Physics from the Ecole Supérieure de Physique et Chimie Industrielles (ESPCI) and a Masters in Medical Instrumentations, Paris France – 1985.

*Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions.

R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs.
In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (Major adverse cardiovascular events).

R-One received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. Based in Rouen, France, Robocath has more than 40 employees.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.